Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: using biotherapies rationally
- 30 April 2004
- journal article
- editorial
- Published by Elsevier in Joint Bone Spine
- Vol. 71 (2) , 91-94
- https://doi.org/10.1016/j.jbspin.2003.10.007
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Signal transduction by tumor necrosis factor and its relativesTrends in Cell Biology, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Identification of TIAR as a Protein Binding to the Translational Regulatory AU-rich Element of Tumor Necrosis Factor α mRNAJournal of Biological Chemistry, 1999
- The Role of 3′ Poly(A) Tail Metabolism in Tumor Necrosis Factor-α RegulationJournal of Biological Chemistry, 1997
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- Genetic influence on cytokine production and fatal meningococcal diseaseThe Lancet, 1997
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.Proceedings of the National Academy of Sciences, 1990
- The Biology of Cachectin/TNF -- A Primary Mediator of the Host ResponseAnnual Review of Immunology, 1989